OrbiMed Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing
Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s ability to support its valuation.